Biostar Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017
November 20, 2017 at 04:01 pm
Share
Biostar Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company reported loss from operations was $573,381 against $1,961,999 a year ago. Loss before income taxes was $125,186 against $1,563,671 a year ago. Net loss was $125,186 or $0.05 per basic and diluted share against $1,563,671 or $0.71 per basic and diluted share a year ago.
For the nine months, the company reported loss from operations was $3,141,217 against $9,490,821 a year ago. Loss before income taxes was $2,453,722 against $9,086,460 a year ago. Net loss was $2,453,722 or $0.93 per basic and diluted share against $9,086,460 or $4.11 per basic and diluted share a year ago. Net cash provided by operating activities was $4,585,547 against $911,057 a year ago.
Biostar Pharmaceuticals, Inc. (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People's Republic of China (PRC or China). The Company offers over-the-counter (OTC) products and prescription-based pharmaceuticals. The Company's products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people. The Company's products include XinAoxing Oleanolic Acid Capsule, Ganwang Compound Paracetamol Capsule, Tianqi Dysmenorrhea Capsule, Compound Paracetamol and Amantadine Hydrochloride Tablets, Deafness Tongqiao pills and Huangyangning Tablets.
BIOSTAR PHARMACEUTICALS, INC. 